Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome

Jibran Durrani, Jaroslaw P. Maciejewski

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 97–104.

https://doi.org/10.1182/hematology.2019000019

Published: 2019

Journal Articles

Clinical consequences of clonal hematopoiesis of indeterminate potential

David P. Steensma

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 264–269.

https://doi.org/10.1182/asheducation-2018.1.264

Published: 2018

Journal Articles

A brief, but comprehensive, guide to clonal evolution in aplastic anemia

Daria V. Babushok

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 457–466.

https://doi.org/10.1182/asheducation-2018.1.457

Published: 2018

Journal Articles

Aging, hematopoiesis, and the myelodysplastic syndromes

Stephen S. Chung, Christopher Y. Park

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 73–78.

https://doi.org/10.1182/asheducation-2017.1.73

Published: 2017

Journal Articles

Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?

Michael Heuser

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 24–32.

https://doi.org/10.1182/asheducation-2016.1.24

Published: 2016

Journal Articles

Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria

Charles J. Parker

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 208–216.

https://doi.org/10.1182/asheducation-2016.1.208

Published: 2016

Journal Articles

Lymphocytosis, lymphadenopathy: benign or malignant?

Jane N. Winter, LoAnn C. Peterson

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 106–110.

https://doi.org/10.1182/asheducation-2015.1.106

Published: 2015

Journal Articles

The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP)

Luca Malcovati, Mario Cazzola

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 299–307.

https://doi.org/10.1182/asheducation-2015.1.299

Published: 2015

Journal Articles

Game of clones: the genomic evolution of severe congenital neutropenia

Ivo P. Touw

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 1–7.

https://doi.org/10.1182/asheducation-2015.1.1

Published: 2015

Journal Articles

How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?

Edwin Chen, Ann Mullally

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 268–276.

https://doi.org/10.1182/asheducation-2014.1.268

Published: 2014

Journal Articles

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes

Yogen Saunthararajah

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 511–521.

https://doi.org/10.1182/asheducation-2013.1.511

Published: 2013

Journal Articles

Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond

Wesam Ahmed, Richard A. Van Etten

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 189–200.

https://doi.org/10.1182/asheducation-2013.1.189

Published: 2013

Journal Articles

When, how, and what cell source for hematopoietic cell transplantation in first complete remission adult acute lymphoblastic leukemia?

Hillard M. Lazarus, Anjali S. Advani

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 382–388.

https://doi.org/10.1182/asheducation.V2012.1.382.3798359

Published: 2012

Journal Articles

Implications of new prognostic markers in chronic lymphocytic leukemia

Nicholas Chiorazzi

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 76–87.

https://doi.org/10.1182/asheducation.V2012.1.76.3806845

Published: 2012

Journal Articles

Thrombotic disease in the myeloproliferative neoplasms

Anna Falanga, Marina Marchetti

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 571–581.

https://doi.org/10.1182/asheducation.V2012.1.571.3798557

Published: 2012

Journal Articles

Management of Paroxysmal Nocturnal Hemoglobinuria in the Era of Complement Inhibitory Therapy

Charles J. Parker

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 21–29.

https://doi.org/10.1182/asheducation-2011.1.21

Published: 2011

Journal Articles

Immunomodulating Drugs in Myelodysplastic Syndromes

Lionel Adès, Pierre Fenaux

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 556–560.

https://doi.org/10.1182/asheducation-2011.1.556

Published: 2011

Journal Articles

Evidence-Based Mini-Review: Should Patients Over the Age of 60 with INT-2 or High-Risk Myelodysplastic Syndrome Undergo Allogeneic Stem Cell Transplantation Prior to Progression to Acute Myelogenous Leukemia?

Mark A. Schroeder, William Blum

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 322–324.

https://doi.org/10.1182/asheducation-2010.1.322

Published: 2010

Journal Articles

Therapeutic potential of JAK2 inhibitors

Srdan Verstovsek

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 636–642.

https://doi.org/10.1182/asheducation-2009.1.636

Published: 2009

Journal Articles

Darwin and evolutionary tales in leukemia

Mel Greaves

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 3–12.

https://doi.org/10.1182/asheducation-2009.1.3

Published: 2009

NARROW

Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome

Clinical consequences of clonal hematopoiesis of indeterminate potential

A brief, but comprehensive, guide to clonal evolution in aplastic anemia

Aging, hematopoiesis, and the myelodysplastic syndromes

Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?

Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria

Lymphocytosis, lymphadenopathy: benign or malignant?

The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP)

Game of clones: the genomic evolution of severe congenital neutropenia

How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes

Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond

When, how, and what cell source for hematopoietic cell transplantation in first complete remission adult acute lymphoblastic leukemia?

Implications of new prognostic markers in chronic lymphocytic leukemia

Thrombotic disease in the myeloproliferative neoplasms

Management of Paroxysmal Nocturnal Hemoglobinuria in the Era of Complement Inhibitory Therapy

Immunomodulating Drugs in Myelodysplastic Syndromes

Evidence-Based Mini-Review: Should Patients Over the Age of 60 with INT-2 or High-Risk Myelodysplastic Syndrome Undergo Allogeneic Stem Cell Transplantation Prior to Progression to Acute Myelogenous Leukemia?

Therapeutic potential of JAK2 inhibitors

Darwin and evolutionary tales in leukemia

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only